An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions

Niraparib is an oral, potent, highly selective poly-ADP ribose polymerase 1 (PARP1) and PARP2 inhibitor. In most developed countries, it is approved as a maintenance treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with complete or partial response to platin...

Descripción completa

Detalles Bibliográficos
Autores principales: Akay, Melek, Funingana, Ionut-Gabriel, Patel, Grisma, Mustapha, Rami, Gjafa, Ernese, Ng, Tony, Ng, Kenrick, Flynn, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593085/
https://www.ncbi.nlm.nih.gov/pubmed/34363200
http://dx.doi.org/10.1007/s40487-021-00167-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593085/
https://www.ncbi.nlm.nih.gov/pubmed/34363200
http://dx.doi.org/10.1007/s40487-021-00167-z

Ejemplares similares